



SEQUENCE LISTING

<110> MITCHELL, Lloyd G.
OTTO, Edward
MERRIL, Carl R.

<120> TRANS-SPLICING MEDIATED PHOTODYNAMIC THERAPY

<130> 027705.00026

<140> 10/658,617
<141> 2003-09-09

<150> 10/374,784
<151> 2003-02-25

<150> 60/359,948
<151> 2002-02-25

<160> 21

<170> PatentIn version 3.3

<210> 1
<211> 8
<212> RNA
<213> Artificial

<220>
<223> 5' splice site consensus

<400> 1
agguragu

<210> 2
<211> 7
<212> RNA
<213> Artificial

<220>
<223> branchpoint consensus sequence in mammals

<220>
<221> misc_feature
<222> (2)..(2)
<223> n is a, c, g, or u

<400> 2
ynyurac

<210> 3
<211> 7
<212> RNA
<213> Artificial

<220>
<223> yeast branchpoint consensus

<400> 3
uacuaac

7

<210> 4
<211> 7
<212> RNA
<213> Artificial

<220>
<223> yeast consensus branchpoint

<400> 4
uacuaac

7

<210> 5
<211> 8
<212> DNA
<213> Artificial

<220>
<223> GT rich sequences

<400> 5
ygtgtt yy

8

<210> 6
<211> 7
<212> RNA
<213> Artificial

<220>
<223> branchpoint

<400> 6
uacuaac

7

<210> 7
<211> 29
<212> DNA
<213> Artificial

<220>
<223> specific primer 5'

<400> 7
aagcttttac tgctcgttct tcagcacgc

29

<210> 8
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Luc-33R

<400> 8

cagggtcgga ctcgatgaac

20

<210> 9
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Luc-34F

<400> 9
ggatatcgcc ctgatcaaga g

21

<210> 10
<211> 6
<212> DNA
<213> Artificial

<220>
<223> (Fig. 3) functional PTM

<400> 10
gctagc

6

<210> 11
<211> 6
<212> RNA
<213> Artificial

<220>
<223> (Fig. 3) Functional PTM

<400> 11
ccgcgg

6

<210> 12
<211> 47
<212> DNA
<213> Artificial

<220>
<223> (Fig. 3) Functional PTM

<400> 12
tactaactgg tacctcttct tttttttttg atatcctgca gggcggc

47

<210> 13
<211> 6
<212> DNA
<213> Artificial

<220>
<223> (Fig. 7) binding domain

<400> 13
gctagc

6

<210> 14
<211> 6
<212> RNA
<213> Artificial

<220>
<223> (Fig. 7) binding domain

<400> 14
ccgcgg

6

<210> 15
<211> 47
<212> DNA
<213> Artificial

<220>
<223> (Fig. 7) branchpoint

<400> 15
tactaactgg tacctcttct tttttttttg atatcctgca gggcggc

47

<210> 16
<211> 65
<212> DNA
<213> Artificial

<220>
<223> (Fig. 10) Target and PTM sequence

<400> 16
ctcctggcct cgcgagatcc ctctcgtaa gggaggcaag cccgacgtcg tccagattgt

60

ccgca

65

<210> 17
<211> 6
<212> DNA
<213> Artificial

<220>
<223> (Fig. 12) Luc-PTM13

<400> 17
ctgcag

6

<210> 18
<211> 71
<212> DNA
<213> Artificial

<220>
<223> (Fig. 15) Luc-PTM1

<400> 18

ccgcggaaca ttattataac gttgctcgaa tactaactgg tacctcttct tttttttttg 60
atatacctgca g 71

<210> 19
<211> 22
<212> DNA
<213> Artificial

<220>
<223> (Fig. 15) Luc-PTM TSD

<400> 19
ctcgagcacc gatatacgtaa ct 22

<210> 20
<211> 36
<212> DNA
<213> Artificial

<220>
<223> (Fig. 25B) Functional 3' ss

<400> 20
tactaactct cttctttttt ttttgataac caggct 36

<210> 21
<211> 35
<212> DNA
<213> Artificial

<220>
<223> (Fig. 25B) Mutated 3' ss

<400> 21
gaacaccta ctacatacat aacagttaac ccgct 35